FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to biochemistry, in particular to a monoclonal human antibody, specific to alpha-toxin of S. aureus. The claimed invention additionally relates to pharmaceutical compositions for treatment of prevention of the abscess formation in an organ, which contains at least one antibody or one nucleic acid, which codes the said antibody.
EFFECT: invention makes it possible to extend an assortment of antibodies, specific to alpha-toxin of S aureus.
23 cl, 7 dwg, 4 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODIES FOR SPECIFIC BINDING OF STAPHYLOCOCCUS AUREUS ALPHA-TOXIN AND METHODS OF APPLICATION | 2012 |
|
RU2620065C2 |
ANTIBODIES AGAINST TEICHOIC ACID CONJUGATE AND THEIR CONJUGATES | 2014 |
|
RU2687044C2 |
STAPHYLOCOCCUS AUREUS CLUMPING FACTOR A (ClfA) ANTIBODY | 2019 |
|
RU2818805C2 |
COMPOSITIONS AND METHODS OF TREATING FUNGAL AND BACTERIAL PATHOGENS | 2014 |
|
RU2717306C2 |
COMBINATIONS OF ANTIBODIES TO STAPHYLOCOCCUS AUREUS | 2019 |
|
RU2804815C2 |
COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF INFECTIONS CAUSED BY STAPHYLOCOCCUS AUREUS | 2015 |
|
RU2636780C1 |
STAPHYLOCOCCUS AUREUS LEUKOCIDINS, THERAPEUTIC COMPOSITIONS AND THEIR APPLICATION | 2011 |
|
RU2677140C1 |
STAPHYLOCOCCUS AUREUS LEUKOCIDINS, THERAPEUTIC COMPOSITIONS AND THEIR USE | 2018 |
|
RU2795545C2 |
STAPHYLOCOCCUS AUREUS LEUKOCIDINS, THERAPEUTIC COMPOSITIONS AND THEIR APPLICATION | 2011 |
|
RU2644237C2 |
ANTIBODIES FOR TREATMENT OF INFECTION AND DISEASES ASSOCIATED WITH CLOSTRIDIUM DIFFICILE | 2011 |
|
RU2630663C9 |
Authors
Dates
2014-10-10—Published
2010-08-10—Filed